Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar; Natalie S. Callander; Kehinde Adekola; Larry D. Anderson; Muhamed Baljevic; Rachid Baz; Erica Campagnaro; Jorge J. Castillo; Caitlin Costello; Christopher D’Angelo; Benjamin Derman; Srinivas Devarakonda; Noura Elsedawy; Alfred Garfall; Kelly Godby; Jens Hillengass; Leona Holmberg; Myo Htut; Carol Ann Huff; Malin Hultcrantz; Yubin Kang; Sarah Larson; Hans Lee; Michaela Liedtke; Thomas Martin; James Omel; Timothy Robinson; Aaron Rosenberg; Douglas Sborov; Mark A. Schroeder; Daniel Sherbenou; Attaya Suvannasankha; Jason Valent; Asya Nina Varshavsky-Yanovsky; Jenna Snedeker; Rashmi Kumar

Journal ArticleOPEN ACCESS

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Kumar S
Callander N
Adekola K
et al.

Journal of the National Comprehensive Cancer Network (2024) 22(1D) 1-19

DOI: 10.6004/jnccn.2024.0001

N/ACitations

15Readers

Abstract

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Cite

CITATION STYLE

APA

Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., … Kumar, R. (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(1D), 1–19. https://doi.org/10.6004/jnccn.2024.0001

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Abstract

Cite

Register to see more suggestions